Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.40 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CDC7 | O00311 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 5/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20122825 | 1.00 | KDM4E (0.44) | KDM4EROCK2RPS6KA5DHODHLMNA | |
| SCHEMBL20122826 | 0.89 | KDM4E (0.42) | KDM4EROCK2RPS6KA5DHODHLMNA | |
| SCHEMBL30664295 | 0.86 | ROCK2 (0.41) | ROCK2KDM5AMETAP2CYP1A2MAPT | |
| SCHEMBL20122794 | 0.86 | ROCK2 (0.41) | ROCK2KDM5AMETAP2CYP1A2MAPT | |
| SCHEMBL29756290 | 0.84 | ROCK2 (0.38) | ROCK2RPS6KA5KDM5AMETAP2CYP1A2 | |
| SCHEMBL20122823 | 0.84 | ROCK2 (0.38) | ROCK2RPS6KA5KDM5AMETAP2CYP1A2 | |
| SCHEMBL20122870 | 0.84 | ROCK2 (0.43) | ROCK2KDM5AMETAP2CYP1A2 | |
| SCHEMBL30664279 | 0.84 | ROCK2 (0.43) | ROCK2KDM5AMETAP2CYP1A2 | |
| SCHEMBL30664293 | 0.82 | METAP2 (0.44) | ROCK2KDM5AMETAP2CYP1A2TGFBR1 | |
| SCHEMBL20122892 | 0.82 | METAP2 (0.44) | ROCK2KDM5AMETAP2CYP1A2TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333412-A1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | SANOFI SA (FR) | 2025-10-30 | — | — | US | disclosed |
| US-12275733-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | SANOFI (FR) | 2025-04-15 | — | — | US | disclosed |
| US-20240182469-A1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | SANOFI (FR) | 2024-06-06 | — | — | US | disclosed |
| US-11827633-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | SANOFI (FR) | 2023-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827633-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | COL2A1, IDO1, COL1A1 | KDM4E 706/4885ROCK2 1093/4885RPS6KA5 1602/4885 |
| US-20240182469-A1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | COL2A1, IDO1, COL1A1 | KDM4E 706/4885ROCK2 1093/4885RPS6KA5 1602/4885 |
| US-12275733-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | COL2A1, IDO1, COL1A1 | KDM4E 706/4885ROCK2 1093/4885RPS6KA5 1602/4885 |
| US-20250333412-A1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | COL2A1, IDO1, COL1A1 | KDM4E 723/4885ROCK2 1100/4885RPS6KA5 1608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.